The Section 503B Bulks List is the FDA list of bulk drug substances that federally-registered outsourcing facilities (large-scale compounding facilities operating under Section 503B of the Federal Food, Drug, and Cosmetic Act) can use to prepare compounded drugs. Where Section 503A operates under state pharmacy board licensure for individual-patient prescriptions, Section 503B operates under FDA registration for bulk manufacturing at outsourcing facilities. The 503B pathway allows large-scale sterile compounding for office use, hospital use, and other institutional distribution.
The GLP-1 chapter is the most consequential 503B story in the site's coverage window. Compounded semaglutide, tirzepatide, and liraglutide surged through the 503B and 503A pathways during the FDA-declared shortages (2022-2024). As the shortages resolved through 2025, the FDA began restricting the shortage-based compounding pathway. On April 30, 2026, the FDA published a proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which if finalized would close the last legal pathway for large-scale outsourcing-facility compounding of the branded GLP-1 molecules. The public comment period closed July 30, 2026.
Enforcement layered alongside the rulemaking. The FDA issued over 50 warning letters to compounding pharmacies and outsourcing facilities in 2024-2025. Adverse-event reports for compounded GLP-1s continue accumulating in FDA Adverse Event Reporting System (FAERS): 990 for compounded semaglutide and over 730 for compounded tirzepatide as of the July 2026 FDA safety statement. Telehealth platforms including Hims & Hers Health (NYSE: HIMS) and LifeMD have migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure.
Stories here cover 503B rulemaking, GLP-1 exclusion timing, enforcement actions, and the parallel-track 503A pathway that governs individual-patient compounding. See [[503a-bulks-list]], [[peptide-compounding]], and [[compounding]] for adjacent threads.
The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026 after a Federal Register-extended deadline from the original June 29 cutoff. The FDA's underlying finding: no clinical need for FDA-registered outsourcing facilities to compound the three GLP-1 molecules from bulk drug substances. Section 503B outsourcing facilities are the FDA-registered large-scale compounding manufacturers (as distinct from state-licensed 503A pharmacies that compound for individual patient prescriptions). Finalization of the proposed rule would close the last legal pathway for large-scale FDA-registered 503B outsourcing facility compounding of the branded GLP-1 molecules, following the December 2024 semaglutide shortage resolution and February 2025 tirzepatide shortage resolution that ended the shortage-based compounding pathway. FDA rulemaking to finalize the exclusion after comment-period close typically takes 3-9 months depending on the volume and substance of received comments. Telehealth platforms including Hims & Hers Health (NYSE: HIMS) and LifeMD have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure. FDA Adverse Event Reporting System (FAERS) data as of the July 2026 safety statement: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide.
A 2026 chemistry study documented that when tirzepatide is compounded with vitamin B12 (a common differentiating additive used by compounding pharmacies to distinguish compounded products from the FDA-approved Mounjaro and Zepbound Eli Lilly formulations), the two substances can chemically bond and form a new molecule not present in the FDA-approved drug product. The finding adds to the accumulating pharmacovigilance case against compounded GLP-1 formulations, which are marketed as bioequivalent to the branded products but frequently contain non-FDA-approved additives whose long-term safety, immunogenicity, and pharmacokinetic profiles have not been characterized in registered clinical trials. Compounding-pharmacy additives often introduce impurities and reaction products that differ from the branded label chemistry. The chemistry-specific finding on tirzepatide + B12 bonding is the type of documented novel-molecule outcome that FDA safety scientists cited in the underlying rationale for the April 30, 2026 proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List. FDA Adverse Event Reporting System (FAERS) data as of July 2026: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide. The FDA 503B comment period on the exclusion closed Thursday July 30, 2026.
July 2026 closed as the most consequential peptide-and-obesity policy month in the site's coverage window. Regulatory milestones: the July 1 Medicare GLP-1 Bridge Program launch providing Wegovy (semaglutide), Zepbound KwikPen (tirzepatide), and Foundayo (orforglipron) at $50/month capped copay for approximately 3.8 million eligible Medicare Part D beneficiaries through December 31, 2027; the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session recommending 6 of 7 research peptides for the Section 503A Bulks List (BPC-157 8-6-1, KPV 8-6-1, TB-500 8-6, MOTS-c 7-5-2, Semax 8-5, Epitalon 7-4; Emideltide/DSIP rejected); the July 30 close of the 503B GLP-1 Bulks List exclusion comment period on the April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide; and the Section 232 pharmaceutical tariffs effective date July 31. Product milestones: the July 16 FDA approval of Merck LIPFENDRA (enlicitide) as the first once-daily oral macrocyclic peptide PCSK9 inhibitor (56-59% LDL reduction in CORALreef Phase 3, $315/month launch pricing); the July 7 FDA accelerated approval of Vera Therapeutics TRUTAKNA (atacicept-vymj) for primary IgA nephropathy; the July 17 FDA traditional approval of Novartis Fabhalta (iptacopan) for IgAN; the July 23 Arrowhead Redemplo (plozasiran) Phase 3 SHASTA-3 and SHASTA-4 positive readout (79-81% triglyceride reduction). Industry milestones: the July 19-20 Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide; the July 21 Novo Nordisk lawsuit and July 24 TRO filing against Eli Lilly over GLP-1 advertising; the July 20-23 EMA CHMP recommendation for lerodalcibep (Lyrokaul) monthly PCSK9 fusion protein.
The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026. If the FDA finalizes the rule, large-scale FDA-registered 503B outsourcing facilities will no longer be able to legally prepare compounded semaglutide, tirzepatide, or liraglutide once the shortage-based compounding pathway has fully closed. The 503B exclusion is the parallel-track regulatory action to the July 23-24 PCAC vote on the 7 research peptides for the 503A Bulks List. Where 503A operates under state pharmacy board licensure for individual-patient prescriptions, 503B operates under FDA registration for bulk manufacturing at outsourcing facilities. The 503A vote broadened access to 6 of 7 research peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP rejected). The 503B exclusion narrows access for the branded GLP-1 franchise. Both actions require FDA rulemaking to formalize, with typical timelines of 6-18 months from the date the agency decides to act. Telehealth companies including Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure.
The FDA updated its Section 503A bulks drug substances list on May 14, 2026, continuing the rolling-status changes leading into the July 23-24 PCAC meeting that will evaluate seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) for potential 503A-bulks-list inclusion. The April 30 503B bulks-list proposal (closing June 29) is moving in parallel toward effectively ending large-scale 503B compounding of semaglutide, tirzepatide, and liraglutide. The combined regulatory cycle through July 24 will reshape the compounding-pharmacy economy for the next 2-3 years and determine which research peptides remain accessible through licensed channels.